Protein kinase N promotes cardiac fibrosis in heart failure by fibroblast-to-myofibroblast conversion.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
12 Sep 2024
Historique:
received: 13 12 2023
accepted: 26 08 2024
medline: 13 9 2024
pubmed: 13 9 2024
entrez: 12 9 2024
Statut: epublish

Résumé

Chronic fibrotic tissue disrupts various organ functions. Despite significant advances in therapies, mortality and morbidity due to heart failure remain high, resulting in poor quality of life. Beyond the cardiomyocyte-centric view of heart failure, it is now accepted that alterations in the interstitial extracellular matrix (ECM) also play a major role in the development of heart failure. Here, we show that protein kinase N (PKN) is expressed in cardiac fibroblasts. Furthermore, PKN mediates the conversion of fibroblasts into myofibroblasts, which plays a central role in secreting large amounts of ECM proteins via p38 phosphorylation signaling. Fibroblast-specific deletion of PKN led to a reduction of myocardial fibrotic changes and cardiac dysfunction in mice models of ischemia-reperfusion or heart failure with preserved ejection fraction. Our results indicate that PKN is a therapeutic target for cardiac fibrosis in heart failure.

Identifiants

pubmed: 39266515
doi: 10.1038/s41467-024-52068-0
pii: 10.1038/s41467-024-52068-0
doi:

Substances chimiques

Protein Kinase C EC 2.7.11.13
protein kinase N EC 2.7.1.-
p38 Mitogen-Activated Protein Kinases EC 2.7.11.24

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7638

Subventions

Organisme : Japan Science Society
ID : 23H02903

Informations de copyright

© 2024. The Author(s).

Références

Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199–210 (2008).
pubmed: 18161745 pmcid: 2693329 doi: 10.1002/path.2277
Wijsenbeek, M., Suzuki, A. & Maher, T. M. Interstitial lung diseases. Lancet 400, 769–786 (2022).
pubmed: 35964592 doi: 10.1016/S0140-6736(22)01052-2
Ginès, P. et al. Liver cirrhosis. Lancet 398, 1359–1376 (2021).
pubmed: 34543610 doi: 10.1016/S0140-6736(21)01374-X
Henderson, N. C., Rieder, F. & Wynn, T. A. Fibrosis: from mechanisms to medicines. Nature 587, 555–566 (2020).
pubmed: 33239795 pmcid: 8034822 doi: 10.1038/s41586-020-2938-9
Savarese, G. & Lund, L. H. Global public health burden of heart failure. Card. Fail. Rev. 3, 7–11 (2017).
pubmed: 28785469 pmcid: 5494150 doi: 10.15420/cfr.2016:25:2
Schelbert, E. B. et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J. Am. Heart Assoc. 4. https://doi.org/10.1161/jaha.115.002613 (2015).
González, A., Schelbert, E. B., Díez, J. & Butler, J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J. Am. Coll. Cardiol. 71, 1696–1706 (2018).
pubmed: 29650126 doi: 10.1016/j.jacc.2018.02.021
Tarbit, E., Singh, I., Peart, J. N. & Rose’Meyer, R. B. Biomarkers for the identification of cardiac fibroblast and myofibroblast cells. Heart Fail. Rev. 24, 1–15 (2019).
pubmed: 29987445 doi: 10.1007/s10741-018-9720-1
Talman, V. & Ruskoaho, H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 365, 563–581 (2016).
pubmed: 27324127 pmcid: 5010608 doi: 10.1007/s00441-016-2431-9
Owan, T. E. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J. Med. 355, 251–259 (2006).
pubmed: 16855265 doi: 10.1056/NEJMoa052256
Mohammed, S. F. et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131, 550–559 (2015).
pubmed: 25552356 doi: 10.1161/CIRCULATIONAHA.114.009625
Redfield, M. M. & Borlaug, B. A. Heart failure with preserved ejection fraction: a review. JAMA 329, 827–838 (2023).
pubmed: 36917048 doi: 10.1001/jama.2023.2020
Tallquist, M. D. Cardiac fibroblast diversity. Annu. Rev. Physiol. 82, 63–78 (2020).
pubmed: 32040933 pmcid: 10939057 doi: 10.1146/annurev-physiol-021119-034527
Wei, K., Nguyen, H. N. & Brenner, M. B. Fibroblast pathology in inflammatory diseases. J. Clin. Investig. 131. https://doi.org/10.1172/jci149538 (2021).
Tallquist, M. D. & Molkentin, J. D. Redefining the identity of cardiac fibroblasts. Nat. Rev. Cardiol. 14, 484–491 (2017).
pubmed: 28436487 pmcid: 6329009 doi: 10.1038/nrcardio.2017.57
Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-β: the master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325–338 (2016).
pubmed: 27108839 doi: 10.1038/nrneph.2016.48
Bretherton, R., Bugg, D., Olszewski, E. & Davis, J. Regulators of cardiac fibroblast cell state. Matrix Biol 91-92, 117–135 (2020).
pubmed: 32416242 pmcid: 7789291 doi: 10.1016/j.matbio.2020.04.002
Amano, M. et al. Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Science 271, 648–650 (1996).
pubmed: 8571127 doi: 10.1126/science.271.5249.648
Watanabe, G. et al. Protein kinase N (PKN) and PKN-related protein rhophilin as targets of small GTPase Rho. Science 271, 645–648 (1996).
pubmed: 8571126 doi: 10.1126/science.271.5249.645
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
pubmed: 12471243 doi: 10.1126/science.1075762
Shimokawa, H., Sunamura, S. & Satoh, K. RhoA/Rho-Kinase in the Cardiovascular System. Circ. Res. 118, 352–366 (2016).
pubmed: 26838319 doi: 10.1161/CIRCRESAHA.115.306532
Jin, Y. J. et al. Protein kinase N2 mediates flow-induced endothelial NOS activation and vascular tone regulation. J. Clin. Investig. 131. https://doi.org/10.1172/jci145734 (2021).
Sakaguchi, T. et al. Protein Kinase N promotes stress-induced cardiac dysfunction through phosphorylation of myocardin-related transcription factor A and disruption of its interaction with actin. Circulation 140, 1737–1752 (2019).
pubmed: 31564129 doi: 10.1161/CIRCULATIONAHA.119.041019
Murray, E. R. et al. Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion. Cell Rep. 38, 110227 (2022).
pubmed: 35081338 pmcid: 8810397 doi: 10.1016/j.celrep.2021.110227
Thumkeo, D., Watanabe, S. & Narumiya, S. Physiological roles of Rho and Rho effectors in mammals. Eur. J. Cell Biol. 92, 303–315 (2013).
pubmed: 24183240 doi: 10.1016/j.ejcb.2013.09.002
Kanemaru, K. et al. Spatially resolved multiomics of human cardiac niches. Nature 619, 801–810 (2023).
pubmed: 37438528 pmcid: 10371870 doi: 10.1038/s41586-023-06311-1
Flynn, P., Mellor, H., Casamassima, A. & Parker, P. J. Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide-dependent protein kinase. J. Biol. Chem. 275, 11064–11070 (2000).
pubmed: 10753910 doi: 10.1074/jbc.275.15.11064
Dong, L. Q. et al. Phosphorylation of protein kinase N by phosphoinositide-dependent protein kinase-1 mediates insulin signals to the actin cytoskeleton. Proc. Natl Acad. Sci. USA 97, 5089–5094 (2000).
pubmed: 10792047 pmcid: 25786 doi: 10.1073/pnas.090491897
Miwa, H. & Era, T. Generation and characterization of PDGFRα-GFPCreERT2 knock-In mouse line. Genesis 53, 329–336 (2015).
pubmed: 25884589 doi: 10.1002/dvg.22853
Ma, Y., Iyer, R. P., Jung, M., Czubryt, M. P. & Lindsey, M. L. Cardiac fibroblast activation post-myocardial infarction: current knowledge gaps. Trends Pharmacol. Sci. 38, 448–458 (2017).
pubmed: 28365093 pmcid: 5437868 doi: 10.1016/j.tips.2017.03.001
Frangogiannis, N. Transforming growth factor-β in tissue fibrosis. J. Exp. Med. 217, e20190103 (2020).
pubmed: 32997468 pmcid: 7062524 doi: 10.1084/jem.20190103
Frangogiannis, N. G. Cardiac fibrosis. Cardiovasc. Res. 117, 1450–1488 (2021).
pubmed: 33135058 doi: 10.1093/cvr/cvaa324
Rudat, C., Norden, J., Taketo, M. M. & Kispert, A. Epicardial function of canonical Wnt-, Hedgehog-, Fgfr1/2-, and Pdgfra-signalling. Cardiovasc. Res. 100, 411–421 (2013).
pubmed: 24000064 doi: 10.1093/cvr/cvt210
Molkentin, J. D. et al. Fibroblast-specific genetic manipulation of p38 mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis. Circulation 136, 549–561 (2017).
pubmed: 28356446 pmcid: 5548661 doi: 10.1161/CIRCULATIONAHA.116.026238
Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577–584 (2003).
pubmed: 14534577 doi: 10.1038/nature02006
Corre, I., Paris, F. & Huot, J. The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. Oncotarget 8, 55684–55714 (2017).
pubmed: 28903453 pmcid: 5589692 doi: 10.18632/oncotarget.18264
Westermann, D. et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ. Heart Fail. 4, 44–52 (2011).
pubmed: 21075869 doi: 10.1161/CIRCHEARTFAILURE.109.931451
Schiattarella, G. G. et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568, 351–356 (2019).
pubmed: 30971818 pmcid: 6635957 doi: 10.1038/s41586-019-1100-z
Jacques, D. C., Pinsky, M. R., Severyn, D. & Gorcsan, J. 3rd Influence of alterations in loading on mitral annular velocity by tissue Doppler echocardiography and its associated ability to predict filling pressures. Chest 126, 1910–1918 (2004).
pubmed: 15596692 doi: 10.1378/chest.126.6.1910
Ogilvie, L. M. et al. Hemodynamic assessment of diastolic function for experimental models. Am. J. Physiol. Heart Circ. Physiol. 318, H1139–h1158 (2020).
pubmed: 32216614 pmcid: 7472516 doi: 10.1152/ajpheart.00705.2019
Lam, C. S. P. et al. Sex differences in heart failure. Eur. Heart J. 40, 3859–3868c (2019).
pubmed: 31800034 doi: 10.1093/eurheartj/ehz835
Roskoski, R. Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol. Res. 187, 106552 (2023).
pubmed: 36403719 doi: 10.1016/j.phrs.2022.106552
Frangogiannis, N. G. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol. Aspects Med. 65, 70–99 (2019).
pubmed: 30056242 doi: 10.1016/j.mam.2018.07.001
Fu, X. et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. J. Clin. Investig. 128, 2127–2143 (2018).
pubmed: 29664017 pmcid: 5957472 doi: 10.1172/JCI98215
Shah, S. J. et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 134, 73–90 (2016).
pubmed: 27358439 pmcid: 4930115 doi: 10.1161/CIRCULATIONAHA.116.021884
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D. & van Veldhuisen, D. J. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur. Heart J. 39, 2780–2792 (2018).
pubmed: 29905796 doi: 10.1093/eurheartj/ehy301
Zile, M. R. et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131, 1247–1259 (2015).
pubmed: 25637629 pmcid: 4390480 doi: 10.1161/CIRCULATIONAHA.114.013215
Tong, D. et al. Female sex is protective in a preclinical model of heart failure with preserved ejection fraction. Circulation 140, 1769–1771 (2019).
pubmed: 31738599 pmcid: 6993895 doi: 10.1161/CIRCULATIONAHA.119.042267
Villalobos, E. et al. Fibroblast primary cilia are required for cardiac fibrosis. Circulation 139, 2342–2357 (2019).
pubmed: 30818997 pmcid: 6517085 doi: 10.1161/CIRCULATIONAHA.117.028752
Kong, P. et al. Opposing actions of fibroblast and cardiomyocyte Smad3 signaling in the infarcted myocardium. Circulation 137, 707–724 (2018).
pubmed: 29229611 doi: 10.1161/CIRCULATIONAHA.117.029622
Doza, Y. N., Cuenda, A., Thomas, G. M., Cohen, P. & Nebreda, A. R. Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are phosphorylated in chemically stressed KB cells. FEBS Lett. 364, 223–228 (1995).
pubmed: 7750576 doi: 10.1016/0014-5793(95)00346-B
Chang, L. & Karin, M. Mammalian MAP kinase signalling cascades. Nature 410, 37–40 (2001).
pubmed: 11242034 doi: 10.1038/35065000
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e3529 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).
pubmed: 29409532 pmcid: 5802054 doi: 10.1186/s13059-017-1382-0
Germain, P. L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res 10, 979 (2021).
pubmed: 35814628 doi: 10.12688/f1000research.73600.1
Ishihama, S. et al. LPL/AQP7/GPD2 promotes glycerol metabolism under hypoxia and prevents cardiac dysfunction during ischemia. FASEB J. 35, e22048 (2021).
pubmed: 34807469 doi: 10.1096/fj.202100882R
Fan, Q. et al. Dectin-1 Contributes to myocardial ischemia/reperfusion injury by regulating macrophage polarization and neutrophil infiltration. Circulation 139, 663–678 (2019).
pubmed: 30586706 doi: 10.1161/CIRCULATIONAHA.118.036044
Pacher, P., Nagayama, T., Mukhopadhyay, P., Bátkai, S. & Kass, D. A. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat. Protoc. 3, 1422–1434 (2008).
pubmed: 18772869 pmcid: 2597499 doi: 10.1038/nprot.2008.138

Auteurs

Satoya Yoshida (S)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Tatsuya Yoshida (T)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Kohei Inukai (K)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Katsuhiro Kato (K)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Yoshimitsu Yura (Y)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Tomoki Hattori (T)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Atsushi Enomoto (A)

Department of Pathology, Nagoya University School of Medicine, Nagoya, Japan.

Koji Ohashi (K)

Department of Molecular Medicine and Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Takahiro Okumura (T)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Noriyuki Ouchi (N)

Department of Molecular Medicine and Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Haruya Kawase (H)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.
Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.

Nina Wettschureck (N)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.

Stefan Offermanns (S)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.

Toyoaki Murohara (T)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.

Mikito Takefuji (M)

Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan. takefuji@med.nagoya-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH